Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 35 resultados

STREXIT2: A PRAGMATIC CLINICAL STUDY OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VERSUS SURGERY ALONE FOR... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 Retroperitoneal sarcomas are rare diseases refractory to treatment with dismal prognosis. Surgery is the only standard approach to primary d...
2023-06-01 - 2028-05-31 | Financiado

LEGATO: Lomustine with or without reirradiation for first progression of glioblastoma: a pragmatic randomize... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 Recurrent glioblastoma is an invariably fatal refractory cancer with dismal prognosis. Patients suffer from low quality of life and very bur...
2023-06-01 - 2028-05-31 | Financiado

DE-ESCALATE: INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHAS... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL tramitó un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 Prostate Cancer is the most common cancer in European men. Despite dramatic improvements in early diagnostic and local treatment, one out of...
2023-04-21 - 2028-05-31 | Financiado

OPTIMA: Optimal treatment for patients with solid tumours in Europe through Artificial intelligence EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individua...
2021-10-18 - 2026-09-30 | Financiado

SISAQOL-IMI: Establishing international standards in the analysis of patient reported outcomes and health related... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL tramitó un H2020: H2020-JTI-IMI2-2019-18-two-stage Measuring and quantifying how a patient feels or functions during treatment is an important endpoint in cancer clinical trials. It is genera...
2020-11-09 - 2024-12-31 | Financiado

RadoNorm: Towards effective radiation protection based on improved scientific evidence and social consideratio... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL participó en un H2020: NFRP-2019-2020 RadoNorm is designed to initiate and perform research and technical development in support of European Union Member States, Associated Count...
2020-05-18 - 2025-08-31 | Financiado

IMMUcan: Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL tramitó un H2020: H2020-JTI-IMI2-2017-13-two-stage IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material...
2019-04-23 - 2025-08-31 | Financiado

HTx: Next Generation Health Technology Assessment to support patient centred societally oriented real t... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL participó en un H2020: H2020-SC1-BHC-2018-2020 HTx will create a framework for next generation Health Technology Assessment (HTA) that supports patient-centred, societally oriented, and r...
2018-12-03 - 2024-06-30 | Financiado

PIONEER: Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Prostate Cancer (PCa) is the second leading cause of cancer, among men in Europe. There are currently major unmet needs in this field, such...
2018-06-14 - 2023-10-31 | Financiado

IB4SD-TRISTAN: Imaging Biomarkers IBs for Safer Drugs Validation of Translational Imaging Methods in Drug Safety... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL tramitó un H2020: H2020-JTI-IMI2-2015-07-two-stage 1.Our consortium has broad, deep experience of drug development and imaging biomarker (IB) validation. We are internationally recognized exp...
2017-03-10 - 2024-12-31 | Financiado

HARMONY: Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY Sofia ref.... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL participó en un H2020: H2020-JTI-IMI2-2015-06-two-stage Despite significant recent progress in the field of hematological malignancies (HMs), with increasing survival rates and improvement in qual...
2016-12-22 - 2023-06-30 | Financiado

MoTriColor: Molecularly guided trials with specific treatment strategies in patients with advanced newly molecul... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL participó en un H2020: H2020-PHC-2014-2015 Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease with distinct molecular subtypes. These subtypes have di...
2015-04-16 - 2020-11-30 | Financiado

CANCER-ID: Cancer treatment and monitoring through identification of circulating tumour cells and tumour relate... EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL participó en un FP6: Blood-based biomarkers such as Circulating Tumor Cells (CTCs), circulating free tumor DNA (cfDNA) and microRNAs (miRNAs) have the potential...
2015-01-01 - 2019-12-31 | Financiado

GETREAL: Incorporating real-life clinical data into drug development EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL participó en un FP6: When a new medicine reaches the market, it is accompanied by an extensive data package that provides information about the safety and effica...
2013-10-01 - 2017-03-31 | Financiado

QUIC-CONCEPT: QUantitative Imaging in Cancer: CONnecting CEllular Processes with Therapy EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL tramitó un FP6: The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell proli...
2011-09-01 - 2018-06-30 | Financiado

QUIC-CONCEPT: QUantitative Imaging in Cancer CONnecting CEllular Processes with Therapy EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL tramitó un FP7: The QuIC-ConCePT consortium has 2 objectives: 1.(90% of resource, WP2-5) to qualify 3 specific imaging biomarkers (IBs) of tumour cell prol...
Financiado

EORTC